| Literature DB >> 27819306 |
Juha P Väyrynen1,2, Shivaprakash J Mutt3, Karl-Heinz Herzig2,3,4, Sara A Väyrynen1,2, Tiina Kantola1,2, Toni Karhu3, Tuomo J Karttunen1,2, Kai Klintrup2,5, Jyrki Mäkelä2,5, Markus J Mäkinen1,2, Anne Tuomisto1,2.
Abstract
Deficiency of vitamin D is associated with increased risk of several types of cancer including colorectal cancer (CRC). However, factors contributing to low levels of 25-hydroxyvitamin D [25(OH)D] in CRC are not clear. Therefore, in this study serum 25(OH)D levels in 117 CRC patients and 86 controls were analyzed and correlated with the clinicopathological data including morphological subtype (serrated or conventional), quantity of tumor infiltrating immune cells, levels of systemic inflammatory markers, and disease outcome. We found that the patients had lower serum 25(OH)D levels compared to the controls. Interestingly, among the patients mismatch repair deficiency, serrated morphology, and high body mass index associated with lowest serum 25(OH)D levels. In addition, patients operated in summer or autumn had higher serum 25(OH)D levels. Furthermore, serum 25(OH)D levels inversely correlated with several systemic inflammatory markers, e.g. serum C reactive protein, but did not associate with prognosis. Mechanism leading to vitamin D deficiency in these patients are not clear but could be related to the effects of systemic inflammation. Longitudinal studies are warranted to assess vitamin D deficiency as a potential risk factor for serrated colorectal polyps and adenocarcinoma.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27819306 PMCID: PMC5098144 DOI: 10.1038/srep36519
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Serum 25(OH)D levels in colorectal cancer patients in relation to clinical and pathological characteristics.
| serum 25(OH)D, nmol/L, median (IQR) | p value | |
|---|---|---|
| Gender | ||
| Male (n = 58) | 52.7 (38.3–69.5) | 0.204 |
| Female (n = 59) | 47.6 (37.7–58.5) | |
| Age | ||
| <65 years (n = 43) | 50.2 (37.7–60.8) | 0.746 |
| ≥65 years (n = 74) | 48.6 (38.9–66.5) | |
| Body mass index | ||
| <25 (n = 47) | 50.4 (37.4–67.0) | 0.0032 |
| 25–30 (n = 46) | 52.7 (45.2–70.5) | |
| >30 (n = 22) | 39.8 (31.7–46.4) | |
| Time of operation | ||
| Winter (Dec-Feb) (n = 21) | 43.6 (30.2–58.1) | 0.012 |
| Spring (Mar-May) (n = 34) | 42.3 (34.2–54.6) | |
| Summer (Jun-Aug) (n = 41) | 53.6 (46.1–70.7) | |
| Autumn (Sep-Nov) (n = 21) | 52.6 (45.1–63.9) | |
| Tumor location | ||
| Proximal colon (n = 49) | 46.1 (34.9–54.5) | 0.116 |
| Distal colon (n = 28) | 55.9 (43.9–66.3) | |
| Rectum (n = 40) | 51.6 (39.7–71.0) | |
| Morphology | ||
| Conventional (n = 89) | 52.6 (40.5–65.1) | 0.029 |
| Serrated (n = 28) | 42.9 (31.0–52.7) | |
| TNM Stage | ||
| Stage I (n = 19) | 60.8 (44.7–75.3) | 0.420A |
| Stage II (n = 46) | 48.1 (37.4–56.0) | |
| Stage III (n = 32) | 48.1 (38.9–71.7) | |
| Stage IV (n = 18) | 49.8 (31.0–60.3) | |
| Depth of invasion | ||
| T1 (n = 5) | 45.3 (38.3–78.7) | 0.267 |
| T2 (n = 19) | 60.8 (41.3–76.9) | |
| T3 (n = 83) | 47.9 (37.1–57.8) | |
| T4 (n = 9) | 60.2 (41.1–69.2) | |
| Nodal metastasis | ||
| N0 (n = 69) | 50.0 (38.7–64.2) | 0.939 |
| N1 (n = 27) | 48.8 (35.8–71.3) | |
| N2 (n = 19) | 50.6 (41.3–59.5) | |
| Distant metastasis | ||
| M0 (n = 98) | 49.0 (39.1–66.5) | 0.513 |
| M1 (n = 18) | 49.8 (31.0–60.3) | |
| WHO Grade 1–3 | ||
| Grade 1 (n = 16) | 56.0 (37.0–71.0) | 0.205 |
| Grade 2 (n = 86) | 50.3 (39.1–62.1) | |
| Grade 3 (n = 14) | 43.1 (33.6–55.8) | |
| Mismatch repair (MMR) enzyme status | ||
| MMR-deficient (n = 11) | 35.3 (32.0–45.5) | 0.018 |
| MMR-proficient (n = 105) | 50.4 (39.9–66.2) | |
| BRAF or KRAS mutation | ||
| BRAF mutation (n = 12) | 42.7 (35.3–62.2) | 0.512 |
| KRAS mutation (n = 30) | 47.2 (37.1–67.4) | |
| No BRAF nor KRAS mutation (n = 74) | 52.6 (39.7–64.1) | |
| Modified Glasgow Prognostic score (mGPS) | ||
| 0 (n = 91) | 50.6 (39.2–69.4) | 0.050 |
| 1–2 (n = 26) | 46.1 (33.8–53.9) | |
Abbreviations: IQR: interquartile range. The p-values are for Mann-Whitney or Kruskal-Wallis test.
AStage I vs. II-IV: p = 0.119.
Correlations between serum 25(OH)D and systemic inflammatory markers.
| serum 25(OH)D | ||
|---|---|---|
| Pearson r | p value | |
| Serum C-reactive protein | ||
| Blood Leukocyte count | ||
| Blood Neutrophil count | ||
| Blood Lymphocyte count | 0.058 | 0.535 |
| Blood Neutrophil/lymphocyte ratio | ||
| Serum IL-1ra | ||
| Serum IL-4 | −0.037 | 0.688 |
| Serum IL-6 | ||
| Serum IL-7 | −0.094 | 0.311 |
| Serum IL-8 | −0.130 | 0.162 |
| Serum IL-9 | −0.030 | 0.746 |
| Serum IL-12(p70) | −0.081 | 0.383 |
| Serum IFNγ | −0.036 | 0.697 |
| Serum CXCL10 | −0.037 | 0.694 |
| Serum CCL2 | 0.020 | 0.831 |
| Serum CCL4 | 0.030 | 0.744 |
| Serum CCL11 | 0.163 | 0.079 |
| Serum PDGF-BB | −0.146 | 0.116 |
Numbers indicate Pearson correlation coefficients (r) for logarithmically transformed variables.
Two multiple linear regression models of the determinants of serum 25(OH)D levels in CRC patients.
| Independent | Beta | p value |
|---|---|---|
| Model 1 (n = 115; R = 0.394, R2 = 0.155) | ||
| Age | 0.157 | 0.082 |
| Measurement in summer or autumn (no vs. yes) | 0.311 | 6.8E-4 |
| Body mass index | −0.106 | 0.234 |
| Serrated morphology (no vs. yes) | −0.175 | 0.049 |
| Model 2 (n = 115; R = 0.450, R2 = 0.202) | ||
| Age | 0.142 | 0.106 |
| Measurement in summer or autumn (no vs. yes) | 0.266 | 0.0028 |
| Serrated morphology (no vs. yes) | −0.178 | 0.039 |
| Blood neutrophil count | −0.246 | 0.0051 |
Model 1 included patient age as a basic clinical variable and three other clinicopathological variables with the highest statistical significance in the univariate analyses (BMI, season of measurement, and serrated histology). Model 2 was constructed to test, whether also systemic inflammatory markers had independent predictive value on serum 25(OH)D levels. Serum 25(OH)D, blood neutrophil count, and body mass index were logarithmically transformed because of positive skewness.
Figure 1Kaplan-Meier curves demonstrating the associations between serum 25(OH)D levels and disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS).
(A) Serum 25(OH)D and DFS. (B) Serum 25(OH)D and CSS. (C) Serum 25(OH)D and OS. Abbreviations: CI: confidence interval; HR: hazard ratio.